Cagrilintide + Tirzepatide

$ 6,000.00

One-time purchase

$ 6,000.00 MXN

Subscribe and save

$ 5,100.00 MXN

Deliver every month, 15% off

Auto-renews, skip or cancel anytime.

To add to cart, go to the product page and select a purchase option

Cagrilintide + Tirzepatide represents a next-generation multi-hormonal peptide combination designed to explore synergistic mechanisms in weight regulation, insulin sensitivity, appetite control, and metabolic health.

By pairing Cagrilintide, a long-acting amylin and calcitonin receptor agonist, with Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, this blend enables researchers to examine the integrated hormonal crosstalk that governs satiety, glucose control, and energy expenditure across metabolic systems.

Preclinical and early clinical data indicate that this dual approach produces greater body-weight reduction and improved glycemic control than incretin or amylin analogs alone—making it a powerful model for studying obesity, diabetes, and metabolic remodeling.

Each peptide in this formulation complements the other: Cagrilintide enhances satiety and gastric regulation, while Tirzepatide amplifies insulin response and lipid metabolism for a comprehensive metabolic research tool.

Formulated in high-purity, research-grade quality, this product is ideal for advanced studies in metabolic flexibility, incretin synergy, endocrine peptide engineering, and long-term energy homeostasis.

Reconstitution Volume:
2 mL

PEPTIDES4ALL Cagrilintide + Tirzepatide is a cutting-edge peptide combination that unites two of the most advanced agents in metabolic research—Cagrilintide, a long-acting amylin analogue, and Tirzepatide (LY3298176), a dual GIP/GLP-1 receptor co-agonist. Together, they form a multi-hormonal research model designed to mimic and amplify the body’s natural regulatory systems for appetite, glucose metabolism, energy balance, and lipid processing.

This synergistic formulation provides a multi-dimensional platform for exploring metabolic remodeling, obesity physiology, and endocrine cross-talk between incretin and amylin pathways.
While GLP-1 and GIP receptor activation enhances insulin release, satiety, and glucose utilization, Cagrilintide further amplifies these effects by targeting the amylin and calcitonin receptor network, promoting delayed gastric emptying, sustained fullness, and reduced caloric intake.
The combined activation of these pathways offers a potent model for investigating next-generation metabolic interventions, multi-receptor peptide design, and energy-homeostasis mechanisms across organ systems.

Mechanistic research has demonstrated that dual or triple-pathway peptide co-agonists can surpass the efficacy of single incretin analogues, producing superior results in fat-mass reduction, insulin sensitivity, and lipid metabolism. As such, this blend represents a valuable tool for preclinical and translational metabolic studies.

Scientific Evidence & Research Findings

Enhanced Weight Reduction: Clinical and preclinical data show that combining Cagrilintide with incretin agonists leads to greater mean weight loss compared to monotherapy—often exceeding the effects seen with GLP-1 analogues alone.
Source: PubMed ID: 34798060
Improved Glycemic Control: Tirzepatide’s dual incretin signaling (GIP + GLP-1) improves insulin secretion, postprandial glucose control, and β-cell responsiveness, complementing the satiety-driven effects of Cagrilintide.
Source: New England Journal of Medicine (2022)
Multi-Hormonal Synergy: Together, these peptides activate complementary neuroendocrine pathways—linking hypothalamic satiety centers, pancreatic β-cell function, and lipid oxidation processes.
Source: “Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Metabolic Dysfunction–Associated Conditions”
Lipid & Hepatic Improvements: Research suggests positive shifts in lipid profiles, hepatic fat content, and liver biomarkers with dual or triple agonist designs, indicating potential value in NASH and fatty liver studies.
Source: “Tirzepatide, a dual GIP/GLP-1 receptor co-agonist… effective weight reduction and glycaemic control in type 2 diabetes”
Energy Balance & Homeostasis: Cagrilintide’s amylin-mediated gastric regulation complements Tirzepatide’s incretin-driven metabolic acceleration—offering a platform to explore energy efficiency and nutrient partitioning. Source: “Bridging the gap between GLP-1-receptor agonists and…” – Cardiovascular Diabetology (2024)"

Key Research Benefits & Applications

Multi-Receptor Activation: Combines amylin, GIP, and GLP-1 receptor pathways for comprehensive metabolic modulation.
Advanced Weight-Management Model: Supports investigation into appetite suppression, energy expenditure, and fat oxidation.
Glycemic & Lipid Regulation: Enables detailed exploration of insulin sensitivity, lipid metabolism, and β-cell dynamics.
Neuroendocrine Crosstalk: Ideal for studies on hypothalamic signaling, appetite regulation, and hormonal synergy.
Next-Generation Peptide Design: Facilitates research on multi-agonist pharmacology and metabolic drug development.
Translational Potential: Applicable to models of obesity, diabetes, metabolic syndrome, and peptide-based endocrine therapies.

Presentation & Handling

Form: Supplied as lyophilized peptide in sterile vial.
Reconstitution: Use bacteriostatic water or 2% procaine; swirl gently (do not shake vigorously).
Storage: Store at –20 °C, protected from light and moisture. After reconstitution, use according to research protocols and handle under sterile conditions.

Intended Use

For research purposes only. Must be handled in accordance with institutional protocols and ethical guidelines.

Add your analysis content here

You may also like